PORTLAND, IA, UNITED STATES, January 9, 2025 /EINPresswire / -- The factors that are anticipated to impede the growth of the global nucleic acid therapeutics market during the forecast period include, ...

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.TRc4SPmX.js ...

The UK Biobank project, announced today, aims to investigate how fluctuations in protein levels during mid- to late-life may influence <a target= ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter "Meiji") announced that the company has concluded an investment agreement wi ...

Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. The San Diego company has guided for full-year revenue ...

Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response to nucleic acids, according to a recent study.

Principal Financial Group Inc. lessened its stake in shares of Qiagen (NYSE:QGEN – Free Report) by 12.0% in the 3rd quarter, ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks ...

Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm's expertise in customized nucleic ...